The London Stock Exchange is pleased to welcome Medicsight plc to AIM.
Medicsight is the industry leader in the development of Computer-Aided Detection (CAD) and image analysis software to assist in the early detection and diagnosis of disease.
Medicsight helps radiologists analyse Computed Tomography (“CT”) scans to detect and diagnose abnormalities and to monitor them accurately over time. Medicsight’s CAD software has been validated using one of the world’s most comprehensive databases of verified CT scan data.
Medicsight‘s currently marketed products include ColonCAD™ and COLON CAR™, and LungCAD™ and LUNG CAR™ which aid the early detection of cancers, with significant global mortality and morbidity.
Admission to trading follows a Placing of the Company's Ordinary Shares, which raised £32 million before expenses at the Placing Price of £1.10 pence per share. The company will have a market capitalisation of £171 million based on the Placing price.
Commenting today, David Sumner, Chief Executive Officer of Medicsight, said: “We would like to thank our existing and new shareholders for their support. They have recognised the benefits of CAD technology and the substantial opportunities for Medicsight in the medical imaging market. Joining AIM will allow us to aggressively drive the sales of Medicsight’s CAD products as well as enabling us to introduce new products to the company’s portfolio through a combination of internal R&D and acquisitions.”
Collins Stewart Europe Limited is acting as Nominated Adviser and Broker.